KBC Group
TERN

KBC Group’s Terns Pharmaceuticals TERN Stock Holding History

KBC Group’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,683
Closed -$89K – 1880
2026
Q1 		$89K Buy
+1,683
New +$69.1K ﹤0.01% 1396

Other funds holding TERN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

KBC Group's TERN Position: Q2 2026 in Review

KBC Group sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 1,683 shares — an estimated $89K sold.

KBC Group first reported a position in TERN in Q1 2026 and held it in 1 quarter. The position peaked at $89K in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

  • KBC Group reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • KBC Group sold 1,683 Terns Pharmaceuticals shares in Q2 2026, an estimated $89K.
  • KBC Group first reported a position in Terns Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • KBC Group's Terns Pharmaceuticals position peaked at $89K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.